Warnyta Minnaard

Warnyta Minnaard

If the practitioner doesn’t know where the primary tumor is located, they cannot offer a targeted treatment plan, and nor can they give the patient an estimate of their life expectancy.

Back to news

More news

Comprehensive molecular diagnostics closer for more patients thanks to price reduction 

Comprehensive molecular diagnostics closer for more patients thanks to price reduction 

20-01-2026

Hartwig Medical Foundation reduces the price of its OncoAct Whole Genome Sequencing (WGS) service as of January 1, 2026. This …

Dutch Healthcare Institute approves reimbursement of whole genome sequencing (WGS) for targeted cancer treatment 

Dutch Healthcare Institute approves reimbursement of whole genome sequencing (WGS) for targeted cancer treatment 

15-08-2025

The Dutch National Health Care Institute (Zorginstituut Nederland, ZiNL) has approved the reimbursement of whole genome sequencing (WGS) through the …

Erasmus MC Cancer Institute introduces comprehensive DNA testing for CUP cancer patients in EMBRAZE region

Erasmus MC Cancer Institute introduces comprehensive DNA testing for CUP cancer patients in EMBRAZE region

01-08-2021

The Erasmus MC Cancer Institute has started using comprehensive DNA testing for carcinoma of unknown primary (CUP) cancer patients in …

Would you like to be kept up to date with new developments?

Sign up for our newsletters

Want to know more about the complete DNA test?

Visit OncoAct.nl